2024-04-23
Following our in-depth analysis of data from the initial phase Ib study, our analysis revealed that our vaccine candidate ALZ-101 has shown a positive effect on biomarkers closely associated with Alzheimer's disease. This development marks a crucial step forward in…
Read more
2024-04-11
As we could announce last week, all patients in the extension part (part B) of our phase 1b study,… Read more
2024-03-26
Kristina Torfgård our CEO, presented Alzinova and participated in the panel discussion at Redeye Alzheimer Event in Stockholm. Read more
2024-03-12
Last week Alzinova got the opportunity to present at Penser by Carnegie’s company day. CEO Kristina Torfgård talked about… Read more
2024-03-05
Bistock has taken note of the Year-end report for 2023 and contacted Alzinova’s CEO Kristina Torfgård and Business Development Director Sebastian… Read more
2024-02-12
Interview in BioStock with Alzinova’s CEO Kristina Torfgård and CSO Anders Sandberg on the positive results from our phase 1b study with ALZ-101. Read more
2024-02-06
Alzinovas CEO Kristina Torfgård interviewed by Alzheimerfonden regarding the latest clinical development and results from the phase 1b study… Read more
2024-02-05
Redeye has interviewed our CEO, Kristina Torfgård. They discussed the company's primary analysis of phase Ib study data with… Read more
2024-01-11
Last fall, we welcomed Kirsten Harting to Alzinova as our Chief Medical Officer. With a wealth of expertise in… Read more
2024-01-08
Our CEO Kristina Torfgård visits Penserpodden, one of Sweden's largest finance podcasts, and talks about Alzinova and our clinical development… Read more
2023-12-05
Last week, Alzinova AB shared positive topline results from the phase 1b study with our vaccine candidate ALZ-101 against… Read more
2023-12-04
We are happy to share a new interview from Alzheimerfonden with Alzinova ABs CEO, Kristina Torfgård. In the interview,… Read more
2023-12-01
CEO Kristina Torfgård and CSO Anders Sandberg commenting on the positive results. Read more
2023-11-07
Our Business Development Director Sebastian Hansson was recently interviewed in BioStock ahead of BIO-Europe about his expectations and what Alzinova hopes… Read more
2023-10-13
Kristina Torfgård, CEO, presented at Redeye Neurology Event in Stockholm on October 11th. Read more
2023-09-20
September 21, is World Alzheimer's Day, which aims to draw attention to and raise awareness about Alzheimer's disease. In… Read more
2023-09-11
Alzinova's CEO Kristina Torfgård shares her reflections on all the important progress the company has made during the year,… Read more
2023-09-05
September marks the start of World Alzheimer's awareness month. Let's take a moment to reflect on the impact of… Read more
2023-06-12
Last week, our CEO, Kristina Torfgård, and Business Development Director, Sebastian Hansson, participated in one of the major biotech… Read more
2023-06-09
We are delighted to have participated in and sponsored Alzheimerfonden and this year's Alzheimer's Run, a significant event in raising awareness… Read more
2023-05-29
Our CEO Kristina Torfgård and Business Development Director Sebastian Hansson will be at BIO 2023 in Boston 5-8th June. Read more
2023-04-24
Alzinova is currently in the subscription period for warrants of series TO3. Alzinova has already secured subscription commitments of… Read more
2023-04-20
The presentation highlighted the latest advancements in the company's groundbreaking research on Alzheimer's disease. Check it out to learn… Read more
2023-04-05
Updated analysis from Mangold Fondkommission based on the recent milestones achieved by Alzinova that further strengthens the case for the Company. … Read more
2023-04-03
Anders tells more about the new exciting data for the vaccine candidate ALZ-101 and the ADPD conference. Read more
2023-03-29
Alzinovas CEO Kristina Torfgård attended Mangold Insight Day and held an investor presentation. Read more
2023-03-23
Exciting news about the filing of a new patent application for a further developed form of its monoclonal antibody… Read more
2023-03-03
2022 was a year of many successes, with several important milestones achieved. CEO Kristina Torfgård comments the year-end report and… Read more
2023-02-10
Read why Sebastian joined the company and what his mission will be at Alzinova AB. Read more
2023-01-27
Sebastian will be responsible for the continued business development that runs parallel to the further development of the Company's… Read more
2023-01-18
Kristina Torfgård, CEO, commenting on recent exciting events for both the company and the industry in general. Read more
2023-01-13
Alzinova's CEO Kristina Torfgård was interviewed about the accelerated approval of lecanemab… Read more
2023-01-05
Anders tells more about the new exciting data for ALZ-201 antibody and the findings and conclusions as well as… Read more
2023-01-04
In the prestigious journal Alzheimer's Research & Therapy, Alzinova presents preclinical results demonstrating that the ALZ-201 antibody has specificity… Read more
2022-12-23
Alzinova's CEO Kristina Torfgård was interviewed about the latest news on the Companies vaccine candidate ALZ-101 against Alzheimer's disease. Read more
2022-12-19
Watch our CEO Kristina Torfgård, present Alzinova (in Swedish). Read more
2022-12-02
Alzinova's CSO Anders Sandberg was interviewed about the Companies monoclonal antibody ALZ-201 that is presented in a poster presentation… Read more
2022-11-30
This week, Alzinova presents data for the Company's preclinical antibody candidate ALZ-201 at the conference in a poster presentation… Read more
2022-11-15
Alzinova AB presents its company and projects to investors and international pharmaceutical companies at several events during the fall. Next… Read more
2022-11-14
“We see that this outcome proves and further strengthens the company's research because we already have indications that specificity… Read more
2022-11-11
Alzinova is featured in this Sifted article where CEO Kristina Torfgård comments the importance of research hubs such as the AZ BioVentureHub. Read more
2022-11-04
2022-10-24
Watch the new interview (in Swedish). Read more
2022-10-14
2022-10-13
Mangold sees the case for Alzinova's ALZ-101 candidate strengthened considerably. In an updated analysis, Mangold sees advantages in Alzinova's… Read more
2022-09-30
We are happy to see progress in the field of Alzheimer research with new results in the industry that… Read more
2022-09-14
Alzinova AB is a proud sponsor of Alzheimerfonden and will participate in their seminar the 21st of September 2022. CEO Kristina Torfgård together with… Read more
2022-09-07
The company announced that the Data Safety Monitoring Board (DSMB) completed an additional planned safety assessment of the ongoing… Read more
2022-09-01
September marks the start of World Alzheimer's awareness month. It's important to highlight and bring awareness to this devastating… Read more
2022-07-12
Redeye discussed the outlook forward and recent rights issue, among other things. "We believe that Alzinova offers a rare… Read more
2022-06-21
Redeye AB has revisited the Alzinova equity story following continued pipeline progress and the recent rights issue: "We continue to see… Read more